Ventus Therapeutics

Structural bio platform to discover small molecules against hard-to-drug, highly validated innate immunity targets

a16z2019Active

What they do

Problem

Many highly validated innate immunity targets are difficult to drug with small molecules, limiting new therapeutic options.

Solution

It uses a structural biology platform to discover small-molecule drugs against hard-to-drug innate immunity targets.

Who it's for

Drug discovery teams at pharmaceutical and biotechnology companies developing therapies targeting innate immunity.

Hao Wu

PhD; Richard Flavell

PhD

FRS; Judy Lieberman

PhD; Thomas Tuschl

PhD